Previous 10 |
Xilio Therapeutics (NASDAQ:XLO): Q3 GAAP EPS of -$21.27. Press Release Cash and cash equivalents were $99.8 million as of September 30, 2021, compared to $19.2 million as of December 31, 2020. Cash and cash equivalents as of September 30, 2021 do not include $116.3 million in estimated net pr...
Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Selective Anti-CTLA-4 Successfully Closed IPO in Fourth Quarter of 2021, Raising Approximately ...
Extending the three consecutive sessions of losses, the shares of Xilio Therapeutics (XLO -24.0%) have recorded the biggest one-day loss to reach their lowest level since the company IPO last month. The clinical-stage oncology company sought $75.6M in gross proceeds with its IPO for 5.4M shar...
Gainers: Krystal Biotech (NASDAQ:KRYS) +118%, Petros Pharmaceuticals (NASDAQ:PTPI) +96%, Adagio Therapeutics (NASDAQ:ADGI) +69%, iSpecimen (NASDAQ:ISPC) +50%, cbdMD (NYSE:YCBD) +31%. Losers: Fennec Pharmaceuticals (NASDAQ:FENC) -51%,...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced data from preclinical studies of XTX301, an engineered tumor-se...
News, Short Squeeze, Breakout and More Instantly...
Xilio Therapeutics Inc. Company Name:
XLO Stock Symbol:
NASDAQ Market:
Xilio Therapeutics Inc. Website:
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Sh...
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-a...